Physician profile
Ann E Moore
NPI 1750506630
$3,132.81
in general payments reported to CMS, 2019-2025
21 companies · $448 in 2025
The $448 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $176 · 2021: $285 · 2022: $809 · 2023: $685 · 2024: $730 · 2025: $448.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,863.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,862.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $572.29 | 2021-2025 | Benlysta |
| Aurinia Pharma U.S., INC. | $482.40 | 2021-2025 | Lupkynis |
| Astrazeneca Pharmaceuticals LP | $337.35 | 2019-2024 | Farxiga, Lokelma |
| Amgen INC. | $263.26 | 2024-2025 | Tavneos, Parsabiv, Aranesp |
| Travere Therapeutics, INC. | $218.32 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $217.61 | 2019-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $194.80 | 2021-2024 | |
| Mallinckrodt Hospital Products INC. | $162.55 | 2021-2025 | Acthar, Terlivaz |
| Fresenius USA Marketing, INC. | $140.59 | 2019-2025 | Velphoro, Velphoro |
| Novartis Pharmaceuticals Corporation | $101.95 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.85 | 2023-2024 | Jardiance |
| Calliditas Therapeutics US INC. | $71.56 | 2022-2024 | |
| Opko Pharmaceuticals, LLC | $65.74 | 2019-2025 | Rayaldee |
| Vifor Pharma, INC. | $47.28 | 2021-2024 | Veltassa |
| Akebia Therapeutics INC | $46.80 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| La Jolla Pharmaceutical Company | $31.27 | 2021 | |
| Mallinckrodt Enterprises LLC | $28.89 | 2019 | |
| Scpharmaceuticals INC. | $25.23 | 2025 | |
| Lilly USA, LLC | $17.08 | 2024 | Jardiance |
| Ardelyx, INC. | $16.58 | 2025 | Ibsrela |
| Ultragenyx Pharmaceutical INC. | $13.41 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.